Loading cancer entity…
Loading cancer entity…
Variants & evidence
8 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|
| FUBP1 LOSS-OF-FUNCTION1 | |||||||
| (diagnostic) | Diagnostic | D | Supports Positive | 3 | submitted | EID7441FUBP1 truncating mutations occur somatically with high specificity for adult oligodendroglioma and are considered oncogenic in that setting PMID 21817013 · Bettegowda et al., 2011 · Open in CIViC | civic |
| H3-3A K28M1 | |||||||
| (diagnostic) | Diagnostic | C | Supports Positive | 1 | rejected | EID9837Yoshimoto, et al. (2017) analyzed 411 gliomas of Japanese patients (median age of 46 years (ranged between 1 to 87 years)). Direct sequencing revealed H3F3A p.K27R in one 51 years of age oligodendrogl… (full text at CIViC) PMID 28447171 · Yoshimoto et al., 2017 · Open in CIViC | civic |
| H3-3A K28R1 | |||||||
| (diagnostic) | Diagnostic | C | Supports Positive | 1 | submitted | EID9838Yoshimoto, et al. (2017) analyzed 411 gliomas of Japanese patients (median age of 46 years (ranged between 1 to 87 years)). Direct sequencing revealed H3F3A p.K27R in one 51 years of age oligodendrogl… (full text at CIViC) PMID 28447171 · Yoshimoto et al., 2017 · Open in CIViC | civic |
| IDH1 R132H2 | |||||||
| (oncogenic) | Oncogenic | B | Supports Oncogenicity | 3 | submitted | EID13299In a cohort of 1,010 WHO grade II-III diffuse gliomas assessed by direct sequencing, IDH1 R132H was identified in 103/128 (80.5%) oligodendrogliomas and 111/174 (63.8%) anaplastic oligodendrogliomas. … (full text at CIViC) PMID 19554337 · Hartmann et al., 2009 · Open in CIViC | civic |
| AGI-5198 | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID979In pre-clinical studies, an IDH1 inhibitor (AG-5198) impaired growth of glioma / anaplastic oligodendroglioma cell lines with IDH1 R132H mutations. A phase I clinical trial of the AG-120 IDH1 inhibit… (full text at CIViC) PMID 23558169 · Rohle et al., 2013 · Open in CIViC | civic |
| MGMT Promoter Methylation1 | |||||||
| (prognostic) | Prognostic | B | Supports Better Outcome | 4 | accepted | EID490In a study of 152 anaplastic oligodendroglial tumors, 121 samples had MGMT promoter methylation. Those with promoter methylation had better progression-free and overall survival. PMID 19901104 · van den Bent et al., 2009 · Open in CIViC | civic |
| MGMT Underexpression1 | |||||||
| Temozolomide | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID2902In this study, loss of chromosome 1p and low MGMT protein expression were associated with objective response (P < .003 and P < .04, respectively). However, only 54% of the study group had evaluation o… (full text at CIViC) PMID 16541434 · Levin et al., 2006 · Open in CIViC | civic |
| TP53 P72R1 | |||||||
| (prognostic) | Prognostic | B | Does Not Support Poor Outcome | 2 | submitted | EID6932In the evaluation of 275 oligodendroglial tumors, the specific genotype at amino acid 72 of TP53 (Arg/Arg, Arg/Pro, or Pro/Pro) was not associated grade of malignancy (low- vs. high-grade, P = 0.650) … (full text at CIViC) PMID 17854663 · Idbaih et al., 2007 · Open in CIViC | civic |
Data updated 9 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.